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The detection of NPS in hair has become extensively researched in recent years. Although most 
NPS fall into the classes of synthetic cannabinoids and designer cathinones, novel synthetic opioids 
(NSO) have appeared with increasing frequency in the illicit drug supply. While the detection of 
NSO in hair is now well-documented, interpretation of results presents several controversial issues, 
as is quite common in hair analysis. In this study, a UHPLC-MS/MS method able to detect 13 
synthetic opioids (including fentanyl analogs) and metabolites in hair was applied to 293 real 
samples. Samples were collected in the United States between November 2016 and August 2018 
from subjects who had reported heroin use in the past year or had already tested positive to hair 
testing for common opiates. The range, mean and median concentrations were calculated for each 
analyte, in order to draw a preliminary direction for a possible cut-off to discriminate between 
exposure to either low or high quantities of the drug. Over two-thirds (68%) of samples tested 
positive for fentanyl at concentrations between LOQ and 8600 pg/mg. The mean value was 382 
pg/mg and the median was 95 pg/mg. The metabolites norfentanyl and 4-ANPP were also 
quantified and were found between LOQ and 320 pg/mg and between LOQ and 1400 pg/mg, 
respectively. The concentration ratios norfentanyl/fentanyl, 4-ANPP/fentanyl, and norfentanyl/4-
ANPP were also tested as potential markers of active use and to discriminate the intake of fentanyl 
from other analogs. The common occurrence of samples positive for multiple drugs may suggest 
that use is equally prevalent among consumers, which is not the case, as correlations based on 
quantitative results demonstrated. We believe this  set of experimental observations provides a 
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useful starting point for a wide discussion aimed to better understanding positive hair testing for 
fentanyl and its analogs in hair samples.
Keywords: hair; interpretation; synthetic opioids; fentalogs; fentanyl
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Research examining the detection of new psychoactive substances (NPS) in hair has increased in 
recent years (1–9). Most of the initial barriers to testing, mainly related to the commercial 
unavailability of reference standards, have now been overcome. Although most NPS fall into the 
classes of synthetic cannabinoids and designer cathinones, novel synthetic opioids (NSO) have 
appeared with increasing frequency in the illicit drug supply, leading to a progressive increase in 
their consumption, which in turn often leads to severe adverse outcomes, including overdose 
morbidity and mortality (10–14). In fact, in many areas of the United States (US), illicit drugs such 
as heroin are now commonly replaced or cut with new designer opioids, so many drug users are 
unintentionally or unknowingly using these new compounds (15–18). To study this phenomenon, 
toxicologists have developed methods for detecting NSO in hair (19, 20). The analytical methods 
currently available include a well-known pharmaceutically used substance, fentanyl (21), and many 
clandestinely-synthesized derivatives. This group of compounds is sometimes referred to as 
“fentalogs”. Compounds such as sufentanil, alfentanil, remifentanil, and carfentanil (normally 
approved for human or veterinary use) (21) can now be detected in hair samples, together with other 
new synthetic opioids such as AH-7921 (22, 23), MT-45 (24), and U-47700 (25-27). The latter are 
non-fentalogs with different chemical structures which have been involved in intoxication cases and 
mortality in several countries. Fentanyl and its analogs are typically available in powder form, 
which can be used directly or mixed with other substances and then smoked or taken via intranasal 
(28) or intravenous route (29). They can also be pressed into tablets, often as counterfeit forms of 
other opioid pharmaceuticals (for example, hydrocodone pills (30)), or other drug classes 
(alprazolam tablets (31)). 
One of the challenges in the development of validated methods for the analysis and identification of 
fentanyl and its analogs in such a rapidly changing and dynamic market is that analytical reference 
materials may often not be commercially available. Furthermore, interpretation of results is still 
debated among toxicologists, as is quite common in hair analysis (32). The main matters currently 
questioned (in order to provide a definitive interpretation of positive vs. negative results) include: 1) 
the establishment of a reasonable cut-off value for each drug (e.g., in order to discriminate between 
occasional and frequent use or exposure), and 2) the identification of proper metabolites allowing us 
to discriminate direct exposure from external contamination. In the present study, preliminary 
results obtained from a large dataset of real hair samples positive for fentanyl or its analogs are 
discussed. The findings of this study are meant to provide a useful starting point for a wider 
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Reagents and standards for furanyl fentanyl and 4-ANPP were produced by Chiron (Trondheim, 
Norway); reagents and standards for acetyl fentanyl, remifentanil and carfentanil were produced by 
Toronto Research Chemicals (North York, Canada); and reagents and standards for tramadol, 
oxycodone, hydrocodone and norfentanyl were purchased from Sigma-Aldrich (Milan, Italy). 
Reagents and standards for alfentanil, U-47,700, fentanyl, sufentanil and the deuterated internal 
standards (norfentanyl-D5, fentanyl-D5 and oxycodone-D6) were produced by Cerilliant (Round 
Rock, Texas, US). Ultra-pure water was obtained using a Milli-Q® UF-Plus apparatus (Millipore, 
Bedford, MA, USA). All stock standard solutions were prepared in methanol at 1 mg/mL and stored 
at 20°C until used. Working solutions were prepared at the final concentration of 1000 ng/mL by 
dilution with methanol.
Sample preparation
Briefly, about 25 mg of hair was twice-washed with dichloromethane and then methanol (2 mL, 
vortex mixed for 3 min). After complete removal of solvent washes, the hair was dried at room 
temperature by a gentle nitrogen flow and subsequently grinded with a ball mill (Precellys 24, 
Bertin Instruments, Montigny-le-Bretonneux, France). Hair samples were fortified with 2.5 µL of 
an internal standards mixture yielding a final concentration of 0.01 ng/mg. After the addition of 1 
mL of methanol, the samples were incubated at 55°C for 15 h without stirring. Lastly, the organic 
phase was collected and an aliquot of 2 μL was directly injected into the ultra-high performance 
liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) system. Whenever the real 
sample concentrations were found to exceed the highest calibration point, the final extracts were 
diluted with methanol and re-injected into the system.
Apparatus
All analyses were performed using a Shimadzu LC-30A Series system (Shimadzu, Duisburg, 
Germany), interfaced to an API 5500 triple quadrupole mass spectrometer (Sciex, Darmstadt, 
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Germany) equipped with an electrospray Turbo Ion source operating in positive-ion mode. A 
CORTECS UPLC C18 plus column 100 mm × 2.1 mm, 1.6 µm (Waters Corporation, Italy), 
protected by a C18 waters VanGuard pre-column, was used for target analyte separation. The 
column oven was maintained at 45°C and the elution solvents were water/formic acid 5 mM 
(solvent A) and acetonitrile plus formic acid 5 mM (solvent B). After an initial isocratic elution at 
95% A for 0.5 min, the mobile phase composition was varied by a linear gradient (A:B; v/v) from 
95:5 to 50:50 in 3.5 min; then isocratic elution at 50% B was maintained for 0.5 min. The flow rate 
was 0.5 mL/min and the total run time was 6 min including re-equilibration at the initial conditions 
before each injection. MS/MS detection was executed in the selected reaction monitoring (SRM) 
mode. In order to establish appropriate SRM conditions, each analyte was individually infused into 
the electrospray ionization (ESI) capillary while the declustering potential (DP) was adjusted to 
maximize the intensity of the protonated molecular species [M+H]+. The collision energy (CE) was 
set so as to preserve approximately 10% of precursor ion and the cell exit potentials (CXP) were 
also optimized. The SRM transitions were monitored during a time window of ±17.5 s around the 
expected retention time, and the cycle time of the SRM program was 0.100 s. Optimal signals were 
obtained using a source block temperature of 600°C and an ion-spray voltage of 1900 V. Gas 
pressures were set as follows: curtain gas 35 psi, ion source gas (1) 45 psi and ion source gas (2) 50 
psi. 
Methods
A simple, fast, specific and sensitive UHPLC-MS/MS method previously developed and validated 
(19) was applied to detect 13 synthetic opioids (including fentanyl analogs) and metabolites in hair. 
LOD values were in the range 0.1-0.3 pg/mg for all analytes, with the exception of oxycodone 
which was 1.5 pg/mg. Samples were collected in the US between November 2016 and August 2018 
from subjects who had reported heroin use in the last year or were selected among hair samples 
which had already tested positive for common opiates. A total of 293 samples was analyzed. All 
samples were analyzed in their entire length (range 1-20 cm, mean value 4.0 cm).
Statistical analysis
Statistical analysis was performed using MATLAB® version 2018b (MathWorks Inc., Natick, MA, 
USA). The data were initially examined with boxplot graphs, before and after logarithmic (base 10) 
transformation. The normality of log10-transformed data distributions was checked by the 
Page 5 of 21
Confidential material. Please destroy hard copies upon completion of review.































































MATLAB® function “normalitytest”, developed by Öner and Kocakoç, which allowed the 
simultaneous completion of ten normality tests, including four different versions of Kolmogorov-
Smirnov test (i.e., limiting form, Stephens method, Marsaglia method, and Lilliefors test) (33).
The correlation coefficients (r) were calculated on the log10 transformed and autoscaled data using 
the MATLAB® built-in “corrcoef” function, which uses the Pearson correlation formula consisting 
in the ratio of the covariance between two variables over the product of their variance. The obtained 
coefficients were compared with the ones computed using the Spearman correlation formula applied 
on the not transformed data. 
Results
Prevalence of compounds
The range of concentrations, including means and medians, were calculated for each analyte. 
Furthermore, the concentration ratios norfentanyl/fentanyl, 4-ANPP/fentanyl and norfentanyl/4-
ANPP were also evaluated as potential discrimination parameters.
Among the 293 samples, two thirds (67.6%; n=198) tested positive to at least one “fentalog” (Table 
1). Remarkably, all 198 of these samples tested positive for fentanyl, either alone or together with 
other molecules. The most common parent compounds detected were fentanyl, acetyl fentanyl and 
furanyl fentanyl. Concentrations of fentanyl in positive samples ranged between LOQ and 8600 
pg/mg. The mean value was 382  811 pg/mg and the median was 95 pg/mg. Over a third (36.8%) 
of samples (108 samples; 54.5% of those testing positive for fentanyl) tested positive for acetyl 
fentanyl, with concentrations ranging between LOQ and 3200 pg/mg. The mean value was 72  320 
pg/mg and the median was 7 pg/mg. Similarly, 29.7% of samples (87 samples; 43.9% of those 
testing positive for fentanyl) tested positive for furanyl fentanyl, with concentrations ranging 
between LOQ and 590 pg/mg. The mean value was 31  76 pg/mg and the median was 6 pg/mg. 
With regard to metabolites and precursors, norfentanyl was detected in 154 samples (52.6% of all 
samples and 77.8% of samples positive for fentanyl), with concentrations ranging between LOQ 
and 320 pg/mg. The mean value was 38  55 pg/mg and the median was 15 pg/mg. Only 21 
samples (7.0% of all samples and 10.6% of those testing positive for fentanyl) resulted positive for 
fentanyl and negative for norfentanyl, all presenting fentanyl concentrations <13 pg/mg. The 
molecule 4-ANPP was detected in 146 samples (49.8% of all samples and 73.7% of samples 
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positive for fentanyl), with concentrations ranging between LOQ and 1400 pg/mg. The mean value 
was 40  126 pg/mg and the median was 8 pg/mg. Box-plots for the most detected compounds are 
presented in Figure 1. Since the quantitative distribution of the detected compounds was not normal 
(as evident from Figure 1), a 1og10-transformation of the data was executed prior of calculating the 
correlation coefficients. All the transformed variables resulted normally distributed, with p-values 
above the “0.01” significance threshold of for all the Kolmogorov-Smirnov tests (33). Only the 
Lilliefors test yielded p-values below the threshold (p<0.01) for acetyl fentanyl and hydrocodone. 
The correlation coefficients from the application of the Pearson formula on the log10-transformed 
and autoscaled data and from the Spearman algorithm on the autoscaled non-transformed data were 
compared. Since no substantial differences between the two computations were observed, only the 
results from the Pearson formula are reported (the same applies for the calculations in the following 
section). In particular, the correlation matrix showing the correlation coefficients between the sets 
of log10 transformed and autoscaled variables, namely the concentrations trends for each pair of the 
screened compounds, is shown in Figure 2. The highest coefficient (r = 0.85) was observed for 
fentanyl and its metabolite norfentanyl. 
The most common prescription opioids, including oxycodone, hydrocodone and tramadol, were also 
monitored. In particular, oxycodone was detected in 168 samples (57.3% of cases), with 
concentrations ranging between LOQ and 25700 pg/mg. The mean value was 1003  2308 pg/mg 
and the median was 94 pg/mg.
Three concentration ratios were evaluated. First, the ratio between norfentanyl and fentanyl was in 
the range 0.01-0.38, with a mean value of 0.10 and a median of 0.08. Then, the ratio between 4-
ANPP and fentanyl was in the range of 0.01-6.21, with a mean value of 0.23 and a median of 0.05. 
Finally, the ratio between norfentanyl and 4-ANPP was in the range of 0.01-25.0, with a mean value 
of 3.9 and a median of 1.81. 
Co-exposure to fentanyl and more common drugs
A subset of 53 samples positive for fentanyl were also tested for other common drugs of abuse (34, 
35). The direct metabolite of heroin, namely 6-monoacetylmorphine, was detected in 49 samples 
(92.4% of cases), benzoylecgonine, the main metabolite of cocaine, was detected in 45 samples 
(84.9% of cases), methamphetamine and its metabolite amphetamine were detected in 20 samples 
(37.7% of cases). With respect to the prescription opioids included in our panel (19), oxycodone or 
hydrocodone was detected in 35 samples (66.0% of positive cases to fentanyl). The results are 
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summarized in Table 1. A correlation matrix showing the Pearson correlation coefficients between 
the screened compounds (after log10-transformation and autoscaling), including the common drugs 
of abuse, is shown in Figure 3. In general, relatively low correlation coefficients were calculated 
between fentanyl and the other common drugs (ranging from -0.1 to 0.36), with the only exception 
of the pair fentanyl/6-MAM yielding the highest coefficient (r = 0.55). 
 
Discussion
Fentanyl was detected in over two thirds of the tested samples in this analysis. Whenever a sample 
was positive for any NSO compound included in the panel of our targeted method, fentanyl was 
also always present, suggesting that fentanyl is the most prevalent molecule while the less common 
analogs are not consumed in isolation. This is congruent with information obtained from drug 
seizures in the US (36). Unlike synthetic cathinones and synthetic cannabinoids, for which the 
incessant introduction of newly synthesized drugs has turned analytical methods upgrading into a 
“cat and mouse game” (37), for NSO, it seems that laboratories can limit the screening to a few 
(prevalent) molecules. Indeed, fentanyl testing is apparently covering the large majority of opioid 
misuse, likely without the need to screen for uncommon NSO if mere detection of any exposure 
(positive vs. negative) is the ultimate goal of hair analysis.
The fentanyl analogs most frequently detected were acetyl fentanyl and furanyl fentanyl, both 
showing a lower mean concentration with respect to fentanyl. While the former can often be present 
as an impurity in fentanyl preparations, it is likely that the latter was used more directly, possibly as 
an adulterant. These two illicit compounds were the compounds most commonly observed at the 
time of our sample collection in 2016-2018 (36), while other designer fentanyl analogs were only 
rarely detected during this time period. However, the drug landscape continues to evolve rapidly, 
making it necessary to periodically update analytical methods in order to periodically add additional 
target NSO (e.g., 3-methylfentanyl, butyrylfentanyl) to keep the pace with the introduction of new 
drugs into the black market.”  Remarkably, carfentanil, representing the NSO of the highest concern 
because of its pharmacological potency (estimated at being some thousands of times more potent 
than morphine), was detected in only four samples, at very low concentrations. The possible reasons 
for the rare occurrence of samples testing positive to carfentanil are: 1) the low prevalence at the 
time of the sample collection, 2) poor incorporation or low stability of carfentanil in the keratin 
matrix, and/or 3) insufficient sensitivity of the analytical method in relation to the low effective 
dosage. On the other hand, fentanyl itself is possibly potent enough to exclude the need of 
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introducing further potentially lethal substances into the illegal market. Indeed, more investigation 
is still needed before a final interpretation is given for the low occurrence of carfentanil in hair 
testing.
Fentanyl and the other NSO analogs were quantified in a wide range of concentrations. Several 
factors can account for the large variability observed in the data, as it is typical for hair analysis and 
more in general for the incorporation of drugs into the keratin matrix collected from different 
subjects. (9). The most important influencing factor is obviously the ingested doses, together with 
the frequency of drug use. Other inter-individual parameters affecting the measured concentration 
in hair include the melanine content (particularly for basic and hydrophobic substances), the 
individual’s metabolism, and other behavioral and environmental factors (9). Median and box-plot 
calculations were used to draw a preliminary direction for a possible cut-off to discriminate between 
exposures to either low or high quantities of drugs. The median value for fentanyl was 95 pg/mg, a 
value not far from the 200 pg/mg cut-off universally used for opiates (38–40). The main metabolites 
could also be detected in the majority of hair samples supporting the possibility to ascertain active 
use. In particular, norfentanyl could be detected in most samples positive for fentanyl. Only in the 
samples with particularly low fentanyl concentrations, namely <13 pg/mg, norfentanyl could not be 
detected. Thus, this compound proved to be present in increasing concentrations when the fentanyl 
concentration was high. The strong correlation (coefficient of 0.85) between fentanyl and its 
metabolite norfentanyl, also in terms of concentration trends, is clearly visible. Another promising 
marker for the fentalog class is 4-ANPP. This compound is frequently detected in real samples, 
about as often as norfentanyl. However, its presence can be attributed not only to metabolism, but 
also to chemical synthesis, since 4-ANPP is a common precursor of fentanyl and several of its 
analogs. Consequently, it is conceivable to use 4-ANPP as a class-marker when screening for 
fentalogs. In this scenario, the simple detection of 4-ANPP in a real sample could provide evidence 
of fentalog intake, whether exposure is known or unknown.
Three ratios were also evaluated. We believe the ratio norfentayl/fentanyl represents a promising 
marker to ascertain active use and discriminate the intake of fentanyl from other analogs. The 
higher the ratio, the more likely the individual has been exposed to fentanyl. The ratio for 4-
ANPP/fentanyl is difficult to interpret, however, since 4-ANPP may originate from the synthesis 
and/or the metabolism of fentanyl. The ratio for norfentanyl/4-ANPP could lead to different 
interpretations. A low ratio corresponding to high 4-ANPP concentration might indicate external 
contamination of fentanyl, producing higher quantities of the precursor than the metabolite. On the 
other hand, a high level of 4-ANPP and a low level of norfentanyl could also be produced by the 
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intake of fentanyl analogs, corresponding to a different metabolism but a similar chemical 
synthesis. 
On the positive samples, the observed median value for oxycodone was close to the median value of 
fentanyl, despite the fact that fentanyl-based pharmaceutical preparations usually contain amounts 
of active drug 1/10-1/100 lower than those contained in oxycodone preparations. Surely the 
structural differences between the two molecules may result in different physical and chemical 
properties, which in turn influence the incorporation into the keratin matrix. However, the fact that 
the two populations have similar distributions and close median values (despite the pharmaceutical 
preparations available on the market having very different amounts of active principle), this may 
further support the hypothesis that the investigated population had misused fentanyl, namely above 
the therapeutic dosages.
Another source of information is provided by the co-presence of traditional drugs of abuse and 
prescription opioids. The large majority of the tested subjects were positive for fentanyl and heroin 
and/or cocaine simultaneously. It is not possible to deduce whether fentanyl was used separately 
from heroin or cocaine, or whether the heroin or cocaine was cut with fentanyl. However, from a 
quantitative perspective, relatively low correlation coefficients may suggest that subjects who were 
more exposed to fentanyl were less exposed to heroin or cocaine, and vice versa, probably due to 
different sources of the substances. More in general, our findings confirm that many of the subjects 
who use illegal drugs are (perhaps repeatedly) exposed to several substances, knowingly or 
unknowingly. In particular, the subset of considered samples indicated that the intake of cocaine 
was only scarcely correlated with that of fentanyl. Within the class of prescription drugs, a 
significant percentage of subjects tested positive for both fentanyl and oxycodone and/or 
hydrocodone, even though the correlation coefficients are relatively low, indicating the preferential 
consumption may be of a single substance, at least during the period of time corresponding to the 
hair length. This finding may be of interest because it appears to be congruent with one explanation 
of the third wave of opioid deaths (11). According to this theory, the recent increase of fentanyl and 
heroin overdoses is linked to at-risk users who have been driven to fentanyl and heroin in response 
to lessened availability of milder prescription opioids such as tramadol, oxycodone, and 
hydrocodone, thus exposing themselves (perhaps unknowingly) to the even more dangerous family 
of fentalogs. 
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In the gradual interpretation process of hair testing results for a new class of abused substances such 
as NSO, much more experimental data are needed before the routes and mechanisms of hair 
incorporation are clarified, the metabolic pathways are fully understood, and potential 
discrimination factors are identified [9]. However, we believe that the present study provides a 
useful yet preliminary insight into these issues to start a wider discussion aimed to better understand 
the positive hair results observed for fentanyl and analogs.
As long as fentanyl is a commercially available medicinal drug, there is a fine line between 
detectability of therapeutic use vs. illicit use or abuse. However, our preliminary data suggest an 
approximate cut-off value around 100 pg/mg to realistically discriminate between therapeutic intake 
of fentanyl and its abuse.
When the possible occurrence of external contamination is claimed to justify a positive test result 
we believe the detection of the metabolite norfentanyl will sustain the hypothesis of active intake. 
On the other hand, 4-ANPP may represent a useful marker to identify the intake of either fentanyl 
or other fentanyl analogs, since it is found as both a fentanyl metabolite and as an impurity 
produced in the synthesis of fentanyl analogs.
Hair analysis shows that the parent drug – fentanyl - is still the largely predominant abused NSO 
drug in the tested population. Fentanyl abuse is frequently associated with the use of heroin and 
other synthetic NSO (acetyl fentanyl, furanyl fentanyl), more rarely associated with the 
consumption of milder therapeutic NSO (tramadol, oxycodone) and seldom associated with use of 
cocaine. From a general perspective, hair analysis proved once again to represent a fundamental 
approach to understand new phenomena of drug abuse, drug diffusion among selected populations 
on geographical or sociological basis, and drug use patterns, prevalence, and potential unintentional 
exposure as substitution/cutting drug, or impurity.
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Table 1 Summary of results obtained from 293 real hair samples
Target analyte Number of 
positive samples
Range of concentrations 
(pg/mg)
Mean Median
Fentanyl 198 LOQ-8600 382 95
Acetyl fentanyl 108 LOQ-3200 72 7
Furanyl fentanyl 87 LOQ-590 31 6
Norfentanyl 154 LOQ-320 38 15
4-ANPP 146 LOQ-1400 40 8
U-47700 22 LOQ-420 44 5
Carfentanyl 4 LOQ-1.5 1.1 1.2
Prescription opioids
Hydrocodone 211 LOQ-12600 269 24
Tramadol 201 LOQ-34700 606 30
Oxycodone 168 LOQ-25700 551 94
Other drugs of abuse (results in ng/mg, obtained from 53 samples positive to fentanyl)
Heroin metabolites 49 0.06-6.94 0.64 0.18
Cocaine metabolites 45 0.05-7.95 1.65 1.52
Amphetamines 20 0.05-6.01 1.78 1.42
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Figure 1 Box-plots for the most detected compounds 
Figure 2 Correlation matrix for 198 samples positive to fentanyl 
Figure 3 Correlation matrix for 53 samples positive to fentanyl tested also for common drugs of 
abuse
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